Egr1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| EGR1 Protein | |
|---|---|
| Protein Name | EGR1 |
| Gene | EGR1 |
| UniProt ID | P18146 |
| PDB ID(s) | 1AYF, 1P47 |
| Molecular Weight | 59.8 kDa |
| Subcellular Localization | Nucleus |
| Protein Family | C2H2-type zinc finger transcription factor |
EGR1 (Early Growth Response Protein 1) is a zinc-finger transcription factor that regulates immediate-early gene programs in response to neuronal activity, calcium influx, and growth factors. EGR1 activates transcription of genes involved in synaptic plasticity, neurotrophin signaling, and cell survival pathways. It acts as both a transcriptional activator and repressor depending on context.
EGR1 contains three C2H2-type zinc fingers at the C-terminus that mediate DNA binding to the consensus sequence GCG(T/G)GGGCG. The N-terminal region contains transcriptional activation and repression domains.
EGR1 is an immediate-early transcription factor rapidly induced by neuronal activity, calcium influx, growth factors, and stress. It regulates genes involved in synaptic plasticity, learning, memory, cell survival, and differentiation. EGR1 targets include neurotrophic factors (BDNF, NGF), synaptic proteins, and anti-apoptotic genes.
EGR1 functions as an immediate early gene responder:
EGR1 as a neurodegenerative disease biomarker:
| Application | Sample | Utility |
|---|---|---|
| Disease State | Blood/CSF | EGR1 elevated in AD/PD |
| Progression | CSF | Correlates with severity |
| Treatment Response | Blood | Modulates with therapy |
Emerging research areas:
EGR1 expression is altered in Alzheimer's disease (often reduced) and Parkinson's disease. EGR1 has neuroprotective properties through regulation of neurotrophic factors. Dysregulated EGR1 may contribute to memory impairment in AD and may be a therapeutic target.
EGR1-based therapeutic strategies include small molecules that enhance EGR1 activity or expression. Ciliary neurotrophic factor (CNTF) and other growth factors that induce EGR1 are being explored for neuroprotection.
The study of Egr1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.